The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
But again it is very difficult to buy in any volume. I had a small top up earlier as I wanted a round number of shares.
I think an update from the BOD is required. Time to deliver Nigel.
I agree with Leicester thoughts that it does bode well for N4P in the future, although we are far from that point when we'll have pill replacements. From the podcast I asked if we could expect news on that front in 2021 and Nigel said it would be nice but not a guarantee.
It seems from Boris's update that we are expecting to live with Covid for the long term, which means that the pharma industry this will be a good earner for them and they will look to see what opportunity they can have over their competition. Nuvec could be an easy answer, although not in the timescale of Autumn. As we've seen with the vaccines, they are continually updating and improving them, especially with the variants, so there is no reason not to assume the same will be happening with pills being sent out. Maybe we'll be involved in the 2022 rollout of pills?
@MayAnya - I think we're all waiting on news. An update on the US patent would be nice, but only cause a spike similar to the European patent news. Good if you're just trading short term, but for the long term we want to see a collaboration. Update from Evotec studies will help with that and I'm certain that interested parties are already being kept up to date on it's progress.
Morning All, I for one agree with what’s said below, but it’s clear everyone is just holding and waiting patiently. However people say that there is little amount of shares on offer so do you reckon more shares need to be released? Or is it the case of wait for news?
I just think N4P is worth more than what it is right now.
Certainly is nice knowing a pill form is being rolled out on large scale though. Hopefully Nuvec can slide in there nicely when the time is right.
Hi, yes I knew you’d been here a very long time while, apologies if that seemed a hostile response. I was trying to make sure that no newbies thought it was possible to be in a pill format by autumn.
@triflepig. Lipid systems were far more understood way beforehand, our system isn’t going to have anywhere near that timeframe importance as they’ve already met their clinical targets, we’ve now been added to a list of ‘alternative systems’, not a bad position to be in.
Be under no illusion, the markets are enormous and N4P are positioning themselves to receive attention and recognition if the ongoing in vivo study is a success, it’s not a guaranteed successful outcome and the fallout of a bad result will be catastrophic. The numpties on Twitter desperately trying to ramp people into this need to stop.
Dare we dream ladies and gents????? I'm going to be glued to news at 10!!!!! Now is our time!!! : )
Interesting discussions.
It did cross my mind that it maybe us.
If it is probably head close to the £1 mark. Here is hoping for the best.
Very unlikely to be Nuvec in the time scale, but I can see how this is good news for us in the future; mRNA oral vaccination related, on a world wide must have scale.
Looks like we had a big breakthrough. Could be huge RNS if it is us. Looking forward to tomorrow.
Stick to ramping on twitter...
Lol
Don’t talk wet.. we’ve not had a clinical trial yet.
Possible RNS in the morning?
Wonder who might be involved in that?